<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410772</url>
  </required_header>
  <id_info>
    <org_study_id>6655</org_study_id>
    <nct_id>NCT02410772</nct_id>
  </id_info>
  <brief_title>TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens</brief_title>
  <acronym>S31/A5349</acronym>
  <official_title>Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether one or two four-month regimens of
      tuberculosis treatment are as effective as a standard six-month regimen for treatment of
      pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week,
      with direct observation of each dose by a health-care worker at least five of the seven days
      of each week.

      The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and
      pyrazinamide followed by four months of isoniazid and rifampin.

      The first short regimen is a single substitution of rifapentine for rifampin: two months of
      isoniazid, rifapentine, ethambutol, and pyrazinamide, followed by two months of isoniazid and
      rifapentine.

      The second short regimen is a double substitution of rifapentine for rifampin and
      moxifloxacin for ethambutol: two months of isoniazid, rifapentine, moxifloxacin, and
      pyrazinamide, followed by two months of isoniazid, rifapentine, and moxifloxacin.

      Target enrollment is 2500 participants. Each study participant will remain in the study for
      18 months in order to include at least 12 months of evaluation of whether the participant's
      TB recurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:

      Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a
      randomized, open-label, controlled, phase 3 clinical trial

      Hypotheses:

      A) Seventeen (17) week rifapentine-based regimen In previously untreated individuals with
      active drug-susceptible pulmonary tuberculosis treated with eight weeks of rifapentine (P),
      isoniazid (H), pyrazinamide (Z) and ethambutol (E) followed by nine weeks of rifapentine plus
      isoniazid, all given daily throughout, the proportion of participants who experience absence
      of cure (unfavorable outcome) will not be inferior to that observed in participants who are
      treated with a standard regimen (eight weeks of rifampin (R), isoniazid, pyrazinamide and
      ethambutol followed by eighteen weeks of rifampin plus isoniazid), all given daily
      throughout.

      B) Seventeen (17) week rifapentine- plus moxifloxacin-containing regimen In previously
      untreated individuals with active drug-susceptible pulmonary tuberculosis treated with eight
      weeks of rifapentine, isoniazid, pyrazinamide and moxifloxacin (M), followed by nine weeks of
      rifapentine, isoniazid, and moxifloxacin, all given daily throughout, the proportion of
      participants who experience absence of cure (unfavorable outcome) will not be inferior to
      that observed in participants who are treated with a standard regimen (eight weeks of
      rifampin, isoniazid, pyrazinamide and ethambutol followed by eighteen weeks of rifampin plus
      isoniazid), all given daily throughout.

      Phase: 3

      Design: This will be an international, multicenter, randomized, controlled, open-label,
      3-arm, phase 3 non-inferiority trial.

      Population: Patients with newly diagnosed, previously untreated pulmonary tuberculosis.

      Number of Sites: Multiple international sites, primarily sites of the Tuberculosis Trials
      Consortium and the AIDS Clinical Trials Group.

      Study Duration: Duration per participant is approximately 18 months.

      Description of Agent or Intervention: After written informed consent, participants will be
      randomly assigned to receive one of the following oral regimens:

      Regimen 1 (control regimen): 2RHZE/4RH

        -  Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol,
           followed by

        -  Eighteen weeks of daily treatment with rifampin and isoniazid

      Regimen 2 (investigational regimen): 2PHZE/2PH

        -  Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and
           ethambutol, followed by

        -  Nine weeks of daily treatment with rifapentine and isoniazid

      Regimen 3 (investigational regimen): 2PHZM/2PHM

        -  Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and
           moxifloxacin, followed by

        -  Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin

      Objectives:

      Primary:

        -  To evaluate the efficacy of a rifapentine-containing regimen to determine whether the
           single substitution of rifapentine for rifampin makes it possible to reduce to seventeen
           weeks the duration of treatment for drug-susceptible pulmonary tuberculosis

        -  To evaluate the efficacy of a rifapentine-containing regimen that in addition
           substitutes moxifloxacin for ethambutol and continues moxifloxacin during the
           continuation phase to determine whether it is possible to reduce to seventeen weeks the
           duration of treatment for drug-susceptible pulmonary tuberculosis

      Secondary:

        -  To evaluate the safety of the investigational regimens

        -  To evaluate the tolerability of the investigational regimens

        -  To collect and store biospecimens from consenting participants for the purpose of future
           research on discovery and validation of TB biomarkers

        -  To determine the correlation of mycobacterial and clinical markers with time to culture
           conversion, culture status at completion of eight weeks of treatment, treatment failure,
           and relapse.

        -  To conduct a pharmacokinetic/pharmacodynamic (PK/PD) study of the test drugs. The main
           objectives of the PK/PD study are to characterize study drug PK parameters and to
           determine relationships between treatment outcomes and PK parameters.

        -  To evaluate the pharmacokinetics of efavirenz-based antiretroviral treatment among
           patients with TB/HIV co-infection taking efavirenz-based combination antiretroviral
           therapy and TB treatment with rifapentine

      Endpoints:

      Primary Endpoints:

        -  Efficacy: TB disease-free survival at twelve months after study treatment assignment.

        -  Safety: Proportion of participants with grade 3 or higher adverse events during study
           drug treatment

      Secondary Endpoints:

        -  TB disease-free survival at eighteen months after study treatment assignment

        -  Time to stable sputum culture conversion (solid and liquid media considered separately)

        -  Speed of decline of sputum viable bacilli by automated liquid MGIT culture days to
           detection

        -  Proportion of participants who are culture negative at completion of eight weeks of
           treatment (solid and liquid media considered separately)

        -  Sensitivity analyses assuming all participants classified as 'not assessable' have a
           favorable outcome

        -  Discontinuation of assigned treatment for a reason other than microbiological
           ineligibility

        -  Estimated steady state efavirenz PK parameters including mid-dosing interval
           concentration
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TB disease-free survival at twelve months after study treatment assignment</measure>
    <time_frame>twelve months after treatment assignment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with grade 3 or higher adverse events during study drug treatment</measure>
    <time_frame>four or six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB disease-free survival at eighteen months after study treatment assignment</measure>
    <time_frame>eighteen months after treatment assignment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who are culture negative at eight weeks</measure>
    <time_frame>eight weeks</time_frame>
    <description>solid and liquid media considered separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to stable sputum culture conversion</measure>
    <time_frame>four or six months</time_frame>
    <description>solid and liquid media considered separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speed of decline of sputum viable bacilli by automated MGIT days to detection</measure>
    <time_frame>four or six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB disease-free survival at twelve and eighteen months after study treatment assignment assuming all losses to follow-up and non-tuberculosis deaths have an unfavorable outcome</measure>
    <time_frame>eighteen months after study treatment assignment</time_frame>
    <description>Sensitivity analyses assuming all losses to follow-up and non-tuberculosis deaths have an unfavorable outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB disease-free survival at twelve and eighteen months after study treatment assignment assuming all losses to follow-up and non-tuberculosis deaths have a favorable outcome</measure>
    <time_frame>eighteen months after study treatment assignment</time_frame>
    <description>Sensitivity analyses assuming all losses to follow-up and non-tuberculosis deaths have a favorable outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of assigned treatment for a reason other than microbiological ineligibility</measure>
    <time_frame>four or six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efavirenz maximum concentration, area under the time-concentration curve, and half life</measure>
    <time_frame>four months</time_frame>
    <description>Among participants with HIV infection receiving efavirenz-based antiretroviral therapy, these values will be used to estimate steady state efavirenz PK parameters including mid-dosing interval concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid
All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, &lt; 55kg 1000 mg, &gt;= 55-75 kg 1500 mg, &gt;75 kg 2000 mg; ethambutol, &lt; 55kg 800 mg, &gt;= 55-75 kg 1200 mg, &gt;75 kg 1600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid
All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, &lt; 55kg 1000 mg, &gt;= 55-75 kg 1500 mg, &gt;75 kg 2000 mg; ethambutol, &lt; 55kg 800 mg, &gt;= 55-75 kg 1200 mg, &gt;75 kg 1600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin
All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, &lt; 55kg 1000 mg, &gt;= 55-75 kg 1500 mg, &gt;75 kg 2000 mg; moxifloxacin, 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine</intervention_name>
    <description>Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment</description>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Priftin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine and moxifloxacin</intervention_name>
    <description>Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.</description>
    <arm_group_label>Regimen 3</arm_group_label>
    <other_name>Priftin and Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>standard six-month treatment</description>
    <arm_group_label>Regimen 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected pulmonary tuberculosis plus one or both of the following: a) at least one
             sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one
             sputum specimen positive for M. tuberculosis by Xpert MTB/RIF testing, with
             semiquantitative result of 'medium' or 'high' and rifamycin resistance not detected.

          -  Age twelve (12) years or older

          -  A verifiable address or residence location that is readily accessible for visiting,
             and willingness to inform the study team of any change of address during the treatment
             and follow-up period.

          -  Women of child-bearing potential who are not surgically sterilized must agree to
             practice a barrier method of contraception or abstain from heterosexual intercourse
             during study drug treatment.

          -  Documentation of HIV infection status.

          -  For HIV-positive individuals, CD4 T cell count greater than or equal to 100 cells/mm3
             based on testing performed at or within 30 days prior to screening.

          -  Laboratory parameters done at or within 14 days prior to screening:

               -  Serum or plasma alanine aminotransferase (ALT) less than or equal to 3 times the
                  upper limit of normal

               -  Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit
                  of normal

               -  Serum or plasma creatinine level less than or equal to 2 times the upper limit of
                  normal

               -  Serum or plasma potassium level greater than or equal to 3.5 meq/L

               -  Hemoglobin level of 7.0 g/dL or greater

               -  Platelet count of 100,000/mm3 or greater

          -  For women of childbearing potential, a negative pregnancy test at or within seven (7)
             days prior to screening

          -  Karnofsky score greater than or equal to 60

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnant or breast-feeding.

          -  Unable to take oral medications.

          -  Previously enrolled in this study.

          -  Received any investigational drug in the past 3 months.

          -  More than five (5) days of treatment directed against active tuberculosis within 6
             months preceding initiation of study drugs.

          -  More than five (5) days of systemic treatment with any one or more of the following
             drugs within 30 days preceding initiation of study drugs: isoniazid, rifampin,
             rifabutin, rifapentine, ethambutol, pyrazinamide, kanamycin, amikacin, streptomycin,
             capreomycin, moxifloxacin, levofloxacin, gatifloxacin, ofloxacin, ciprofloxacin, other
             fluoroquinolones, ethionamide, prothionamide, cycloserine, terizidone,
             para-aminosalicylic acid, linezolid, clofazimine, delamanid or bedaquiline.

          -  Known history of prolonged QT syndrome.

          -  Suspected or documented tuberculosis involving the central nervous system and/or bones
             and/or joints, and/or miliary tuberculosis and/or pericardial tuberculosis.

          -  Current or planned use within six months following enrollment of one or more of the
             following medications: HIV protease inhibitors, HIV integrase inhibitors, HIV entry
             and fusion inhibitors, HIV non-nucleoside reverse transcriptase inhibitors other than
             efavirenz, quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or
             terfenadine. Individuals who are currently taking efavirenz-based antiretroviral
             treatment or for whom initiation of efavirenz-based antiretroviral treatment is
             planned within 17 weeks following enrollment may participate.

          -  Weight less than 40.0 kg.

          -  Known allergy or intolerance to any of the study medications.

          -  Individuals will be excluded from enrollment if, at the time of enrollment, their M.
             tuberculosis isolate is already known to be resistant to any one or more of the
             following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones.

          -  Other medical conditions, that, in the investigator's judgment, make study
             participation not in the individual's best interest.

          -  Current or planned incarceration or other involuntary detention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Dorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Payam Nahid, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan V Goldberg, MD</last_name>
    <phone>404-639-5339</phone>
    <email>ssg3@cdc.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekaterina (Katya) Kurbatova, MD, PhD, MPH</last_name>
    <phone>404-639-2017</phone>
    <email>ies3@cdc.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>TBTC Site 46/ TBTC Site 1201 University of Southern California, CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis M Mendez, BS</last_name>
      <phone>323-343-8288</phone>
      <email>lmendez@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TBTC Site 85/ ACTG Site 701 UC San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Kunkel, RN</last_name>
      <phone>619-543-8080</phone>
      <email>jkunkel@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TBTC Site 82/ ACTG Site 801 USCF AIDS CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annie Luetkemeyer, MD</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>130</phone_ext>
      <email>annie.luetkemeyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TBTC Site 47/ ACTG Site 31786 New Jersey Medical School CRC Network</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan V Goldberg, MD</last_name>
      <phone>404-639-5339</phone>
      <email>ssg3@cdc.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TBTC Site 24 Columbia Unversity</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neil Schluger, MD</last_name>
      <email>ns311@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mascha Elskamp, RN</last_name>
      <phone>917-359-6315</phone>
      <email>me2500@columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 20 UNTHSC (University of North Texas Health Science Center)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Samuel, MD</last_name>
      <phone>817-321-4948</phone>
      <email>George.Samuel@unthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Edgar Mauricio Vecino, MD</last_name>
      <phone>817-321-4917</phone>
      <email>Edgar.Vecino@unthsc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 40 South Texas Consortium (South Texas Group)</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc H Weiner, MD</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>16060</phone_ext>
      <email>weiner@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Wing, BSN, RN</last_name>
      <phone>956-296-1517</phone>
      <email>wing@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 62 Baylor College of Medicine &amp; Affiliated Hospitals/VA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Guy, MD</last_name>
      <phone>713-873-2338</phone>
      <email>guy@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Reyes, PhD</last_name>
      <phone>713-873-2370</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 63 San Antonio VA Medical Center (South Texas Group)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc H Weiner, MD</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>16060</phone_ext>
      <email>weiner@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Engle, CRT, CCRC</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>16381</phone_ext>
      <email>englem2@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 94/ ACTG Site 12201 Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Breno R Santos, MD</last_name>
      <phone>55 51 3341 5316</phone>
      <email>breno@ghc.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Rita Lira, MD</last_name>
      <phone>55 51 8158 0184</phone>
      <email>Lrita@ghc.com.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 91/ ACTG Site 12101 Insituto Nacional de Pesquisa Clínica Evandro Chagas</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatriz Grinsztejn, MD PhD</last_name>
      <phone>55 21 2270-7064</phone>
      <email>gbeatriz@ini.fiocruz.br</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Wagner Cardozo</last_name>
      <phone>55 21 2270-7064</phone>
      <email>sandra.wagner@ini.fiocruz.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 36 TB and Chest Service of Hong Kong, China</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi C Leung, MBBS</last_name>
      <phone>852-25353864</phone>
      <email>cc_leung@dh.gov.hk</email>
    </contact>
    <contact_backup>
      <last_name>Kwok C Chang, MBBS</last_name>
      <phone>852-25911147</phone>
      <email>kc_chang@dh.gov.hk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 45/ ACTG Site 30022: Les Centres Gheskio (INLR)</name>
      <address>
        <city>Port au Prince</city>
        <state>Ouest</state>
        <zip>HT6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Severe, MD</last_name>
      <phone>509-3764-1180</phone>
      <email>patsevere@gheskio.org</email>
    </contact>
    <contact_backup>
      <last_name>Samuel Pierre, MD</last_name>
      <phone>509-3740-7711</phone>
      <email>pierresamuel1@yahoo.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 67/ ACTG Site 31730 GHESKIO centers IMIS</name>
      <address>
        <city>Port-au-Prince</city>
        <state>Ouest</state>
        <zip>HT 6124</zip>
        <country>Haiti</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Nerette Fontain, MD</last_name>
      <phone>509-3170-8270</phone>
      <email>sandnerette@yahoo.fr; snerette@gheskio.org</email>
    </contact>
    <contact_backup>
      <last_name>Stalz C Vilbrum, MD</last_name>
      <phone>509-3735-6654</phone>
      <email>stalzsog@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 43/ ACTG Site 31441 BJ Medical College</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>4110011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vidya Mave, MD</last_name>
      <phone>2020-26052419</phone>
      <email>vidyamave@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nishi Suryavanshi, Ph.D.</last_name>
      <email>nishisuryavanshi@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 44/ ACTG Site 11701 CART CRS, YRGCARE Medical Centre VHS</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kumarasamy Nagalingeswaran, MBBS, PhD</last_name>
      <phone>91 44 39106812</phone>
      <email>kumarasamy@yrgcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Faith Beaulah, M.Sc.N</last_name>
      <phone>91 44 39106811</phone>
      <email>beulah@yrgcare.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS</name>
      <address>
        <city>Kericho</city>
        <state>Kericho County</state>
        <zip>20200</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederick K Sawe, MBChB MMED</last_name>
      <phone>254 522030686/688</phone>
      <email>Fredrick.Sawe@usamru-k.org</email>
    </contact>
    <contact_backup>
      <last_name>Samwel K Chirchir, KRCHN,HND</last_name>
      <phone>254 522030686/688</phone>
      <email>samwel.chirchir@usamru-k.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 39/ ACTG Site 31460 Kisumu CRS</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza Province</state>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P Cain, MD</last_name>
      <phone>254-572022929</phone>
      <email>bvz1@cdc.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elisha O Okeyo, MD</last_name>
      <phone>254 721410654</phone>
      <email>Eokeyo@kemricdc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 03/ ACTG Site 12601 Moi University Clinical Research Site</name>
      <address>
        <city>Eldoret</city>
        <zip>30100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abraham M Siika, MBChB, Mmed</last_name>
      <phone>254721280785</phone>
      <email>amsiika@africaonline.co.ke</email>
    </contact>
    <contact_backup>
      <last_name>K K Lagat, MBChB, Mmed</last_name>
      <phone>254723958189</phone>
      <email>1drlagat@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 04/ ACTG Site 30301 Blantyre CRS (or College of Medicine - Johns Hopkins Research Project, COM-JHP)</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felluna Chauwa, MPH</last_name>
      <phone>265 1 875 129</phone>
      <email>fchauwa@jhu.medcol.mw</email>
    </contact>
    <contact_backup>
      <last_name>Godwin Ulaya, MBBS</last_name>
      <phone>265 1 875 129</phone>
      <email>gulaya@jhu.medcol.mw</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 05/ ACTG Site 12001 UNC Project Tidziwe Centre</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Martinson, MD PHD</last_name>
      <phone>265 1 755 056</phone>
      <email>fmartinson@unclilongwe.org</email>
    </contact>
    <contact_backup>
      <last_name>Innocent Mofolo</last_name>
      <phone>265 1 755 056</phone>
      <email>imofolo@unclilongwe.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 90/ ACTG Site 11301 Asociacion Civil Impacta Salud y Educacion</name>
      <address>
        <city>Lima</city>
        <zip>Lima 04</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Lama, MD MPH</last_name>
      <phone>51 1 2067800</phone>
      <phone_ext>407</phone_ext>
      <email>jrlama@impactaperu.org</email>
    </contact>
    <contact_backup>
      <last_name>Fanny Rosas, RN</last_name>
      <phone>51 1 2067800</phone>
      <phone_ext>209</phone_ext>
      <email>frosas@impactaperu.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 93/ ACTG Site 11302 CRS San Miguel</name>
      <address>
        <city>Lima</city>
        <zip>Lima 32</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esmeralda Montalban, MD</last_name>
      <phone>511 562 1600</phone>
      <phone_ext>618</phone_ext>
      <email>emontalban@impactaperu.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Rios, CNM</last_name>
      <phone>511 562 1600</phone>
      <phone_ext>643</phone_ext>
      <email>jrios@impactaperu.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 10/ ACTG Site 31718 TASK Applied Science</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas H Diacon, PhD</last_name>
      <phone>27 82 420 1677</phone>
      <email>ahd@sun.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Florian T von Groote-Bidlingmaier, MD</last_name>
      <phone>27 83 584 7996</phone>
      <email>florianv@sun.ac.za</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 09/ ACTG Site 31792 University of Cape Town Lung Institute (Pty) Ltd</name>
      <address>
        <city>Mowbray</city>
        <state>Cape Town</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney Dawson, Assoc. Prof.</last_name>
      <phone>27 21 406 6850</phone>
      <email>rodney.dawson@uct.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TBTC Site 34 Wits Health Consortium Perinatal HIV Research Unit (PHRU)</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Martinson, MD</last_name>
      <phone>+27 (11) 989-9729</phone>
      <email>martinson@phru.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Matebogo Letutu</last_name>
      <phone>+27 11 989 9889</phone>
      <email>letutum@phru.co.za</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 49/ ACTG Site 12301 Soweto ACTG CRS</name>
      <address>
        <city>Soweto</city>
        <state>Johannesburg</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lerato Mohapi, MD</last_name>
      <phone>27 11 989 9700</phone>
      <email>mohapil@phru.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Debra Peters</last_name>
      <phone>011 989-9700</phone>
      <email>petersd@phru.co.za</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 06/ ACTG Site 11201 Durban International Clinical Research Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4093</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umesh Lalloo, MD, Prof</last_name>
      <phone>27312611093</phone>
      <email>umeshlalloo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rosie Mngqibisa, MBChB</last_name>
      <phone>27312611093</phone>
      <email>mngqibisa@ecarefoundation.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 01/ACTG Site 8950 FAM CRU</name>
      <address>
        <city>Parow Valley</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne R Tonsing, Ma.,Psych.</last_name>
      <phone>27 21 938 9399</phone>
      <email>stonsing@sun.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Ciska Botha, B. Soc. Sc.</last_name>
      <phone>27 21 938 4953</phone>
      <email>ciskabotha@sun.ac.za</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 08/ ACTG Site 31793 South African Tuberculosis Vaccine Initiative (SATVI)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7705</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Hikuam, PhD</last_name>
      <phone>27 21 406 6228</phone>
      <email>chris.hikuam@uct.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TBTC Site 07/ ACTG Site 11101 Wits Helen Joseph CRS</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharlaa Badal-Faesen, MD</last_name>
      <phone>27 11 276-8818</phone>
      <email>sfaesen@witshealth.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Mohammed A Rassool, MBChB</last_name>
      <phone>2711276 8813</phone>
      <email>mrassool@witshealth.co.za</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 31 Barcelona Spain</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan A Caylà, MD, PhD</last_name>
      <phone>(0034) 93 238 45 45</phone>
      <phone_ext>359</phone_ext>
      <email>jcayla@aspb.cat</email>
    </contact>
    <contact_backup>
      <last_name>Jose M Miró, MD, PhD</last_name>
      <phone>(0034) 93 227 54 30</phone>
      <email>miro97@fundsoriano.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 42/ ACTG Site 31802 The Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon, MD PHD</last_name>
      <phone>66 2 6523040-9</phone>
      <phone_ext>107</phone_ext>
      <email>anchaleea2009@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sivaporn Gatechompol, MD</last_name>
      <phone>66 2 6523040-9</phone>
      <phone_ext>171</phone_ext>
      <email>sivaporn.k@hivnat.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 69/ ACTG Site 31784 Thai-CTIU, CMU HIV Treatment CRS</name>
      <address>
        <city>Muang Chiang Mai</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daralak Tavornprasit, MSc</last_name>
      <phone>66 53 221966</phone>
      <phone_ext>176</phone_ext>
      <email>daralak@rihes-cmu.org</email>
    </contact>
    <contact_backup>
      <last_name>Sineenart Nimsakul, BA</last_name>
      <phone>66 53 894190</phone>
      <email>snimsakul@rihes-cmu.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 11/ ACTG Site 12401 Joint Clinical Research Centre, Kampala Clinical Research Site</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter N Mugyenyi, MBChB,FCP</last_name>
      <phone>256 752 770 622</phone>
      <email>pmugyenyi@jcrc.org.ug</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Rwambuya, MPH</last_name>
      <phone>256 772 779</phone>
      <phone_ext>283</phone_ext>
      <email>dxr23@case.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 30 Uganda-Case Western Reserve Research Collaboration</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet Mayanja-Kizza, MBChB,MMed</last_name>
      <phone>+256 772 593 482</phone>
      <email>hmk@chs.mak.ac.ug</email>
    </contact>
    <contact_backup>
      <last_name>Grace Muzanyi, MBChB, MSc</last_name>
      <phone>256 786 638 198</phone>
      <email>gxm62@case.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 37 Vietnam NTP/UCSF Research Collaboration</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nhung Nguyen, MD, PhD</last_name>
      <phone>(844) 37614673</phone>
      <email>ssg3@cdc.gov</email>
    </contact>
    <contact_backup>
      <last_name>Ha T Phan, MD, DrPH</last_name>
      <phone>(844) 39728420</phone>
      <email>Ha.Phan@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TBTC Site 41/ ACTG Site 30313 Parirenyatwa Clinical Research Site</name>
      <address>
        <city>Harare</city>
        <zip>263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wadzanai P Samaneka, MB ChB</last_name>
      <phone>2634701717</phone>
      <phone_ext>119</phone_ext>
      <email>wsamaneka@uzcrc.co.zw</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Mahachi, MNS</last_name>
      <phone>2634701326</phone>
      <phone_ext>124</phone_ext>
      <email>rmahachi@uzcrc.co.zw</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Haiti</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>United States</country>
    <country>Vietnam</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centers for Disease Control and Prevention</investigator_affiliation>
    <investigator_full_name>Stefan Goldberg</investigator_full_name>
    <investigator_title>Medical Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data being collected in CDISC format.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

